{"id":1366,"date":"2024-07-19T14:05:36","date_gmt":"2024-07-19T14:05:36","guid":{"rendered":"https:\/\/fhucare2.laurent-angeli.fr\/event\/main-achievements-significant-actions-2020-2024\/"},"modified":"2025-12-25T19:00:48","modified_gmt":"2025-12-25T18:00:48","slug":"main-achievements-significant-actions-2020-2024","status":"publish","type":"post","link":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/event\/main-achievements-significant-actions-2020-2024\/","title":{"rendered":"MAIN ACHIEVEMENTS & SIGNIFICANT ACTIONS 2020-2024"},"content":{"rendered":"

FHU CARE Cancer and Autoimmunity Relationships
<\/strong>MAIN ACHIEVEMENTS & SIGNIFICANT ACTIONS 2020-2024<\/strong><\/span><\/p>\n

TNF SENESCENCE clinical trial<\/strong><\/a> (TNFSEN)<\/span>
Aim: Investigate T cell senescence and exhaustion in autoimmune diseases.<\/span>
Inclusion: 67<\/strong> patients (25 RA, 22 SpA, 20 Sj\u00f6gren’s).<\/span>
Findings: Higher senescence and exhaustion in autoimmune conditions. <\/span>
One article under revision and one submitted.<\/span>
Lead Researchers: Pr. Ga\u00ebtane Nocturne, Pr. Nathalie Chaput-Gras<\/strong>, Dr. Samuel Bitoun.<\/strong><\/span><\/p>\n

CITAR clinical trial (Checkpoint Inhibitors Treatment Arthritis)<\/strong><\/a> <\/span>
Aim: Compare early IL-6R blockade (tocilizumab) vs. glucocorticoids for treating arthritis from cancer immunotherapy.<\/span>
Participants: 112<\/strong> patients, randomized, multicenter trial. Sponsored by Karolinska Institute<\/strong>.<\/span>
Results: First trial center opened in Sweden in March 2024. 8 out of 106 patients included so far.<\/span>
PI for France: Dr. Samuel Bitoun<\/strong>. Scientific Coordinator: Pr. Xavier Mariette<\/strong>.<\/span><\/p>\n

PICASSO clinical trial<\/strong><\/a><\/span>
Goal: Evaluate fecal transplantation combined with immunotherapy on anti-cancer efficacy in metastatic melanoma patients.<\/span>
Participants: 70<\/strong> patients.<\/span>
Status: Recruitment complete, results expected by end of 2024.<\/span>
Lead: Pr. Franck Carbonnel, Patricia Lepage<\/strong>.<\/span><\/p>\n

PREMIS study<\/strong><\/a>
<\/strong>Objective: Identify predictive biomarkers of immunological adverse events from immune checkpoint inhibitors.<\/span>
Participants: 1,000 <\/strong>patients.<\/span>
Results: Multiple publications and ongoing collaborations.<\/span>
Leads: Pr. Aur\u00e9lien Marabelle, Dr. Fran\u00e7ois-Xavier Danlos<\/strong>.<\/span><\/p>\n

SPOC MIRACIP Online Course<\/strong><\/a><\/span>
Content: Management of toxicities associated with anti-cancer immunotherapies.<\/span>
Outcome: Over 200<\/strong> registrations across 2 <\/strong>editions, with participants from 11 <\/strong>countries.<\/span>
Coordinator: Pr. Olivier Lambotte<\/strong>.<\/span><\/p>\n

iTox Symposium 2024<\/strong><\/a><\/span>
Purpose: Update on toxicities associated with anti-cancer immunotherapies, featuring international speakers, including Americans. Organized annually.<\/span>
Date: May 22-23, 2024, at Bic\u00eatre Faculty of Medicine, UPSaclay.<\/span><\/p>\n

ONCOach Podcasts<\/strong><\/a><\/span>
Content: 13 <\/strong>episodes on immunotherapy toxicities, initiated by Dr. Audrey Perret<\/strong>.<\/span>
Audience: Healthcare personnel.<\/span><\/p>\n

Women in Sciences (WiS) Workshops<\/strong><\/a><\/span>
Events: 3<\/strong> editions focusing on women’s health and gender equality in healthcare<\/strong>, with 326 participants.<\/span>
Next Edition: November 20, 2024, at H\u00f4pital Europ\u00e9en Georges Pompidou.<\/span><\/p>\n

European Guidelines for the Management of Immune-related Adverse Events (irAE)<\/strong><\/span>
Lead: Pr. Xavier Mariette<\/strong> led the development of guidelines for the diagnosis and management of rheumatic irAEs.<\/span><\/p>\n

MAIN SUBMITTED PROJECTS<\/strong><\/span>
Funding Applications: FHU CARE has applied for over 50 projects<\/strong>, securing \u20ac2.2 million<\/strong> in funding.<\/span><\/p>\n

DIM ITAC<\/a><\/strong><\/span>
The Paris region (\u00cele-de-France) awarded Pr. Caroline Robert<\/strong> and Pr. Xavier Mariette<\/strong> a Major Interest Domain (DIM) on Immunotherapies, Auto-immunity, and Cancer with funding of \u20ac11 million<\/strong> for 5 years.<\/span><\/p>\n

PUBLICATIONS<\/a> <\/strong>
<\/strong>Total FHU CARE Publications (2021-2024): 135 entries<\/strong>. See the website under the Publications section<\/a><\/strong>.<\/span><\/p>\n

COMMUNICATION AND OUTREACH<\/strong>
<\/strong>Newsletter<\/strong>: News2CARE sent monthly to over 300 contacts<\/strong>.
Social media<\/strong>: Active on LinkedIn<\/a> and Twitter<\/a>.<\/span>
Events Organized<\/strong>: 6<\/strong> General Assemblies, 1 <\/strong>Webinar, 3<\/strong> Scientific Workshops.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

FHU CARE Cancer and Autoimmunity Relationships MAIN ACHIEVEMENTS & SIGNIFICANT ACTIONS 2020-2024 TNF SENESCENCE clinical trial (TNFSEN) Aim: Investigate T cell senescence and exhaustion in autoimmune diseases. Inclusion: 67 patients (25 RA, 22 SpA, 20 Sj\u00f6gren’s). Findings: Higher senescence and exhaustion in autoimmune conditions. One article under revision and one submitted. Lead Researchers: Pr. Ga\u00ebtane […]<\/p>\n","protected":false},"author":1,"featured_media":1367,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"event_date":"2020-2024","event_location":"FHU CARE Mains Achievements","event_time":"","footnotes":""},"categories":[10],"tags":[],"class_list":["post-1366","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-event"],"_links":{"self":[{"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/posts\/1366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/comments?post=1366"}],"version-history":[{"count":2,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/posts\/1366\/revisions"}],"predecessor-version":[{"id":2395,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/posts\/1366\/revisions\/2395"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/media\/1367"}],"wp:attachment":[{"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/media?parent=1366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/categories?post=1366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/tags?post=1366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}